GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (STU:APS) » Definitions » Loans Receivable

Asarina Pharma AB (STU:APS) Loans Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB Loans Receivable?

Asarina Pharma AB's Loans Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


Asarina Pharma AB Loans Receivable Historical Data

The historical data trend for Asarina Pharma AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Loans Receivable Chart

Asarina Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Asarina Pharma AB Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Asarina Pharma AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Asarina Pharma AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Asarina Pharma AB (STU:APS) Business Description

Traded in Other Exchanges
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (STU:APS) Headlines

No Headlines